Patents by Inventor Won Yong HAN

Won Yong HAN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11236146
    Abstract: Disclosed is a stable pharmaceutical formulation, comprising a fusion protein in which the extracellular ligand-binding domain of a human p75 tumor necrosis factor receptor is fused to the Fc domain of human IgG and a succinate buffering agent, without comprising a stabilizer. The stable pharmaceutical formulation enables the long-term storage of the TNFR-Fc fusion protein formulation and can exhibit superior storage stability without the need for demanding storage conditions, and is a simple formulation because no stabilizer is comprised therein and is thus more economical than other stabilizer-comprising formulations.
    Type: Grant
    Filed: October 26, 2017
    Date of Patent: February 1, 2022
    Assignee: Celltrion Inc.
    Inventors: Joon Won Lee, Won Yong Han, Su Jung Kim, Jun Seok Oh, So Young Kim, Kwang Woo Kim, Yeon Kyeong Shin
  • Publication number: 20210347861
    Abstract: A stable liquid pharmaceutical preparation of an anti-influenza virus antibody and, more specifically, a stable liquid pharmaceutical preparation that comprises: (A) an anti-influenza virus antibody or a mixture of two or more different types of anti-influenza virus antibodies; (B) a surfactant; (C) a sugar or a sugar derivative; and (D) an amino acid. The stable liquid pharmaceutical preparation for an anti-influenza virus antibody disclosed herein has excellent storage stability at low temperature (5° C.), room temperature (25° C.), and high temperature (40° C.) and excellent long-term (12 months) storage stability, and may be administered intravenously, intramuscularly, transdermally, subcutaneously, intraperitoneally, topically, or in combinations thereof.
    Type: Application
    Filed: August 9, 2017
    Publication date: November 11, 2021
    Inventors: Joon Won Lee, Won Yong Han, Su Jung Kim, Jun Seok Oh, So Young Kim, Kwang Woo Kim, Yeon Kyeong Shin
  • Publication number: 20210315813
    Abstract: A stable liquid pharmaceutical formulation according to the present invention includes an antibody or antigen-binding fragment thereof, a surfactant, a sugar or a sugar derivative, a buffer, and a stabilizer. The stable liquid pharmaceutical formulation according to the present invention has low viscosity not only when antibody content is low but also when antibody content is high, and exhibits superior long-term storage stability based on superior stability observed under accelerated conditions and harsh conditions.
    Type: Application
    Filed: July 18, 2019
    Publication date: October 14, 2021
    Applicant: CELLTRION INC.
    Inventors: So Young Kim, Yeon Kyeong Shin, Hye Young Kang, Kwang Woo Kim, Jun Seok Oh, Su Jung Kim, Joon Won Lee, Won Yong Han, Jae Bin Lee, Ji Won Roh, Ji Min Kwak
  • Publication number: 20210205454
    Abstract: Disclosed is a stable liquid formulation, comprising an antibody or antigen-binding portion thereof, an acetate buffer, glycine, and a surfactant, wherein the stable liquid formulation does not comprise at least one of sugar, a sugar alcohol and a metal salt, and the stable liquid formulation is still stable even upon high antibody content, and is superior in osmolality and viscosity, and subcutaneous administration thereof is possible.
    Type: Application
    Filed: March 16, 2021
    Publication date: July 8, 2021
    Applicant: CELLTRION INC.
    Inventors: Joon Won LEE, Yeon Kyeong SHIN, Hye Young KANG, Kwang Woo KIM, So Young KIM, Su Jung KIM, Jun Seok OH, Won Yong HAN
  • Patent number: 10980881
    Abstract: Disclosed is a stable liquid formulation, comprising an antibody or antigen-binding portion thereof, an acetate buffer, glycine, and a surfactant, wherein the stable liquid formulation does not comprise at least one of sugar, a sugar alcohol and a metal salt, and the stable liquid formulation is still stable even upon high antibody content, and is superior in osmolality and viscosity, and subcutaneous administration thereof is possible.
    Type: Grant
    Filed: January 10, 2018
    Date of Patent: April 20, 2021
    Assignee: CELLTRION INC.
    Inventors: Joon Won Lee, Yeon Kyeong Shin, Hye Young Kang, Kwang Woo Kim, So Young Kim, Su Jung Kim, Jun Seok Oh, Won Yong Han
  • Publication number: 20210000743
    Abstract: The present invention provides a stable liquid pharmaceutical formulation containing: an antibody or its antigen-binding fragment; a surfactant; a sugar or its derivative; and a buffer. The stable liquid pharmaceutical formulation according to the present invention has low viscosity while containing a high content of the antibody, has excellent long-term storage stability based on excellent stability under accelerated conditions and severe conditions, and may be administered subcutaneously.
    Type: Application
    Filed: June 28, 2017
    Publication date: January 7, 2021
    Inventors: Joon Won Lee, Won Yong Han, Su Jung Kim, Jun Seok Oh, So Young Kim, Su Hyeon Hong, Yeon Kyeong Shin
  • Publication number: 20190343956
    Abstract: Disclosed is a stable liquid formulation, comprising an antibody or antigen-binding portion thereof, an acetate buffer, glycine, and a surfactant, wherein the stable liquid formulation does not comprise at least one of sugar, a sugar alcohol and a metal salt, and the stable liquid formulation is still stable even upon high antibody content, and is superior in osmolality and viscosity, and subcutaneous administration thereof is possible.
    Type: Application
    Filed: January 10, 2018
    Publication date: November 14, 2019
    Applicant: CELLTRION INC.
    Inventors: Joon Won LEE, Yeon Kyeong SHIN, Hye Young KANG, Kwang Woo KIM, So Young KIM, Su Jung KIM, Jun Seok OH, Won Yong HAN
  • Publication number: 20190248871
    Abstract: Disclosed is a stable pharmaceutical formulation, comprising a fusion protein in which the extracellular ligand-binding domain of a human p75 tumor necrosis factor receptor is fused to the Fc domain of human IgG and a succinate buffering agent, without comprising a stabilizer. The stable pharmaceutical formulation enables the long-term storage of the TNFR-Fc fusion protein formulation and can exhibit superior storage stability without the need for demanding storage conditions, and is a simple formulation because no stabilizer is comprised therein and is thus more economical than other stabilizer-comprising formulations.
    Type: Application
    Filed: October 26, 2017
    Publication date: August 15, 2019
    Inventors: Joon Won LEE, Won Yong HAN, Su Jung KIM, Jun Seok OH, So Young KIM, Kwang Woo KIM, Yeon Kyeong SHIN